SPB2StevenBalkSteven Paul Balk, M.D., Ph.D.42.34022770000000-71.1058540000000049595Balk, StevenPaul617/667-3918Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson9730888Exley M, Porcelli S, Furman M, Garcia J, Balk SThe Journal of experimental medicineCD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains. J Exp Med. 1998 Sep 07; 188(5):867-76.J Exp Med1998-09-07T00:00:001998CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains.10070037Saubermann LJ, Probert CS, Christ AD, Chott A, Turner JR, Stevens AC, Balk SP, Blumberg RSThe American journal of physiologyEvidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states. Am J Physiol. 1999 03; 276(3):G613-21.Am J Physiol1999-03-01T00:00:001999Evidence of T cell receptor beta-chain patterns in inflammatory and noninflammatory bowel disease states.6971889Balk SP, Walker J, Mescher MFJournal of immunology (Baltimore, Md. : 1950)Kinetics of cytolytic T lymphocyte binding to target cells in suspension. J Immunol. 1981 Jun; 126(6):2177-83.J Immunol1981-06-01T00:00:001981Kinetics of cytolytic T lymphocyte binding to target cells in suspension.7513663Burke S, Landau S, Green R, Tseng CC, Nattakom T, Canchis W, Yang L, Kaiserlian D, Gespach C, Balk SGastroenterologyRat cluster of differentiation 1 molecule: expression on the surface of intestinal epithelial cells and hepatocytes. Gastroenterology. 1994 May; 106(5):1143-9.Gastroenterology1994-05-01T00:00:001994Rat cluster of differentiation 1 molecule: expression on the surface of intestinal epithelial cells and hepatocytes.7520051Blumberg RS, Balk SPInternational reviews of immunologyIntraepithelial lymphocytes and their recognition of non-classical MHC molecules. Int Rev Immunol. 1994; 11(1):15-30.Int Rev Immunol1994-01-01T00:00:001994Intraepithelial lymphocytes and their recognition of non-classical MHC molecules.9973405Rodionov DG, Nordeng TW, Pedersen K, Balk SP, Bakke OJournal of immunology (Baltimore, Md. : 1950)A critical tyrosine residue in the cytoplasmic tail is important for CD1d internalization but not for its basolateral sorting in MDCK cells. J Immunol. 1999 Feb 01; 162(3):1488-95.J Immunol1999-02-01T00:00:001999A critical tyrosine residue in the cytoplasmic tail is important for CD1d internalization but not for its basolateral sorting in MDCK cells.10436875Blumberg RS, Lencer WI, Zhu X, Kim HS, Claypool S, Balk SP, Saubermann LJ, Colgan SPImmunology lettersAntigen presentation by intestinal epithelial cells. Immunol Lett. 1999 Jun 15; 69(1):7-11.Immunol Lett1999-06-15T00:00:001999Antigen presentation by intestinal epithelial cells.17043241Chen S, Xu Y, Yuan X, Bubley GJ, Balk SPProceedings of the National Academy of Sciences of the United States of AmericaAndrogen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15969-74.Proc Natl Acad Sci U S A2006-10-16T00:00:002006Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.17291291Probert CS, Saubermann LJ, Balk S, Blumberg RSImmunological reviewsRepertoire of the alpha beta T-cell receptor in the intestine. Immunol Rev. 2007 Feb; 215:215-25.Immunol Rev2007-02-01T00:00:002007Repertoire of the alpha beta T-cell receptor in the intestine.11536181Stremmel C, Exley M, Balk S, Hohenberger W, Kuchroo VKEuropean journal of immunologyCharacterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets. Eur J Immunol. 2001 Sep; 31(9):2818-28.Eur J Immunol2001-09-01T00:00:002001Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets.12231036Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart CUrologyOverview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6.Urology2002-09-01T00:00:002002Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.12799378Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SPThe Journal of biological chemistryA direct beta-catenin-independent interaction between androgen receptor and T cell factor 4. J Biol Chem. 2003 Aug 15; 278(33):30828-34.J Biol Chem2003-06-10T00:00:002003A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4.20039304Nowak M, Lynch L, Yue S, Ohta A, Sitkovsky M, Balk SP, Exley MAEuropean journal of immunologyThe A2aR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol. 2010 Mar; 40(3):682-7.Eur J Immunol2010-03-01T00:00:002010The A2aR adenosine receptor controls cytokine production in iNKT cells.20814940Exley MA, Wilson B, Balk SPCurrent protocols in immunologyIsolation and functional use of human NKT cells. Curr Protoc Immunol. 2010 Aug; Chapter 14:Unit 14.11.Curr Protoc Immunol2010-08-01T00:00:002010Isolation and functional use of human NKT cells.15256534Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SPMolecular endocrinology (Baltimore, Md.)Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol. 2004 Oct; 18(10):2388-401.Mol Endocrinol2004-07-15T00:00:002004Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells.3257857Bleicher PA, Balk SPArchives of dermatologyT-cell receptor gene rearrangements. Progress and promise. Arch Dermatol. 1988 Mar; 124(3):359-63.Arch Dermatol1988-03-01T00:00:001988T-cell receptor gene rearrangements. Progress and promise.Authorship 104430918302198Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee GSThe ProstateAndrogen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate. 2008 Jun 01; 68(8):839-48.Prostate2008-06-01T00:00:002008Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.22014572Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SPCancer cellAndrogen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18; 20(4):457-71.Cancer Cell2011-10-18T00:00:002011Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.21868758Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SPCancer researchIntratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15; 71(20):6503-13.Cancer Res2011-08-25T00:00:002011Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Authorship 1036331512089345Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SPMolecular endocrinology (Baltimore, Md.)Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul; 16(7):1492-501.Mol Endocrinol2002-07-01T00:00:002002Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.Authorship 10737382Authorship 10738481929921690Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SPCancer researchNeoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res. 2018 08 15; 78(16):4716-4730.Cancer Res2018-06-19T00:00:002018Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.29930797Xu X, Balk SP, Isaacs WB, Ma JCell & bioscienceCalcium signaling: an underlying link between cardiac disease and carcinogenesis. Cell Biosci. 2018; 8:39.Cell Biosci2018-06-08T00:00:002018Calcium signaling: an underlying link between cardiac disease and carcinogenesis.23023563Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby ACMolecular endocrinology (Baltimore, Md.)In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol. 2012 Nov; 26(11):1836-46.Mol Endocrinol2012-09-28T00:00:002012In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.7535384Balk SNatureMHC evolution. Nature. 1995 Apr 06; 374(6522):505-6.Nature1995-04-06T00:00:001995MHC evolution.22127852Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GM, Kantoff PWThe ProstateThe altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 01; 72(10):1093-103.Prostate2011-11-29T00:00:002011The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer.18045951Barb D, Neuwirth A, Mantzoros CS, Balk SPEndocrine-related cancerAdiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007 Dec; 14(4):995-1005.Endocr Relat Cancer2007-12-01T00:00:002007Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway.Authorship 110169819584279Cai C, Wang H, Xu Y, Chen S, Balk SPCancer researchReactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009 Aug 01; 69(15):6027-32.Cancer Res2009-07-07T00:00:002009Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.Authorship 10807989Authorship 1080825530012673Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SPCancer researchBMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018 09 15; 78(18):5203-5215.Cancer Res2018-07-16T00:00:002018BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.30021909Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen SClinical cancer research : an official journal of the American Association for Cancer ResearchTyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis. Clin Cancer Res. 2018 11 01; 24(21):5458-5470.Clin Cancer Res2018-07-18T00:00:002018Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.22275373Chen S, Gulla S, Cai C, Balk SPThe Journal of biological chemistryAndrogen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem. 2012 Mar 09; 287(11):8571-83.J Biol Chem2012-01-24T00:00:002012Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.7931067Gross GG, Schwartz VL, Stevens C, Ebert EC, Blumberg RS, Balk SPThe Journal of experimental medicineDistribution of dominant T cell receptor beta chains in human intestinal mucosa. J Exp Med. 1994 Oct 01; 180(4):1337-44.J Exp Med1994-10-01T00:00:001994Distribution of dominant T cell receptor beta chains in human intestinal mucosa.8609425Chott A, Probert CS, Gross GG, Blumberg RS, Balk SPJournal of immunology (Baltimore, Md. : 1950)A common TCR beta-chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis. J Immunol. 1996 Apr 15; 156(8):3024-35.J Immunol1996-04-15T00:00:001996A common TCR beta-chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis.18490728van der Vliet HJ, Wang R, Yue SC, Koon HB, Balk SP, Exley MAJournal of immunology (Baltimore, Md. : 1950)Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells. J Immunol. 2008 Jun 01; 180(11):7287-93.J Immunol2008-06-01T00:00:002008Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells.Authorship 1088370330101540Kolodny G, Li X, Balk SBioEssays : news and reviews in molecular, cellular and developmental biologyAddressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries. Bioessays. 2018 10; 40(10):e1800057.Bioessays2018-08-12T00:00:002018Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries.7495730Balk SP, Polischuk JE, Probert C, Stevens C, Ebert E, She J, Terhorst C, Blumberg RSInternational immunologyComposition of TCR-CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain. Int Immunol. 1995 Aug; 7(8):1237-41.Int Immunol1995-08-01T00:00:001995Composition of TCR-CD3 complex in human intestinal intraepithelial lymphocytes: lack of Fc epsilon RI gamma chain.7688787Panja A, Blumberg RS, Balk SP, Mayer LThe Journal of experimental medicineCD1d is involved in T cell-intestinal epithelial cell interactions. J Exp Med. 1993 Sep 01; 178(3):1115-9.J Exp Med1993-09-01T00:00:001993CD1d is involved in T cell-intestinal epithelial cell interactions.8391057Porcelli S, Yockey CE, Brenner MB, Balk SPThe Journal of experimental medicineAnalysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med. 1993 Jul 01; 178(1):1-16.J Exp Med1993-07-01T00:00:001993Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain.8618007Chott A, Vonderheid EC, Olbricht S, Miao NN, Balk SP, Kadin METhe Journal of investigative dermatologyThe dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996 Apr; 106(4):696-700.J Invest Dermatol1996-04-01T00:00:001996The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis.19887483Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchPhase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.Clin Cancer Res2009-11-03T00:00:002009Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.22844460Wang H, Xu Y, Fang Z, Chen S, Balk SP, Yuan XPloS oneDoxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation. PLoS One. 2012; 7(7):e41330.PLoS One2012-07-23T00:00:002012Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation.Authorship 10917151530181386Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PSClinical cancer research : an official journal of the American Association for Cancer ResearchContribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 01 01; 25(1):426-439.Clin Cancer Res2018-09-04T00:00:002018Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.18852122Hodgson MC, Shen HC, Hollenberg AN, Balk SPMolecular cancer therapeuticsStructural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol Cancer Ther. 2008 Oct; 7(10):3187-94.Mol Cancer Ther2008-10-01T00:00:002008Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.20231295Jiang X, Chen S, Asara JM, Balk SPThe Journal of biological chemistryPhosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 2010 May 14; 285(20):14980-14989.J Biol Chem2010-03-15T00:00:002010Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.30242112Russo JW, Gao C, Bhasin SS, Voznesensky OS, Calagua C, Arai S, Nelson PS, Montgomery B, Mostaghel EA, Corey E, Taplin ME, Ye H, Bhasin M, Balk SPCancer researchDownregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res. 2018 11 15; 78(22):6354-6362.Cancer Res2018-09-21T00:00:002018Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.Authorship 109388111Authorship 10928611430217568Russo JW, Liu X, Ye H, Calagua C, Chen S, Voznesensky O, Condulis J, Ma F, Taplin ME, Einstein DJ, Balk SP, Chen SCancer lettersPhosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer Lett. 2018 12 01; 438:97-104.Cancer Lett2018-09-11T00:00:002018Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.23426182Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan XThe Journal of clinical investigationERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar; 123(3):1109-22.J Clin Invest2013-02-15T00:00:002013ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.23239736Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown MScience (New York, N.Y.)EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14; 338(6113):1465-9.Science2012-12-14T00:00:002012EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.HB131HimishaBeltranHimisha Beltran, M.D.173333Beltran, HimishaAssociate Professor of MedicineAuthorship 110383015Authorship 11058351930295334Poluben L, Puligandla M, Neuberg D, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PGAmerican journal of hematologyCharacteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. Am J Hematol. 2019 01; 94(1):62-73.Am J Hematol2018-10-31T00:00:002018Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.30334814Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G, Riisnaes R, Uo T, Neeb A, Welti J, Morrissey C, Carreira S, Luo J, Nelson PS, Balk SP, True LD, de Bono JS, Plymate SRThe Journal of clinical investigationAndrogen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Invest. 2019 01 02; 129(1):192-208.J Clin Invest2018-11-26T00:00:002018Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.2456698Su IJ, Balk SP, Kadin METhe American journal of pathologyMolecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies. Am J Pathol. 1988 Aug; 132(2):192-8.Am J Pathol1988-08-01T00:00:001988Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies.23204237Sowalsky AG, Ye H, Bubley GJ, Balk SPCancer researchClonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res. 2013 Feb 01; 73(3):1050-5.Cancer Res2012-11-30T00:00:002012Clonal progression of prostate cancers from Gleason grade 3 to grade 4.9815822Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchFunctional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997 Aug; 3(8):1383-8.Clin Cancer Res1997-08-01T00:00:001997Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.8496608Blumberg RS, Yockey CE, Gross GG, Ebert EC, Balk SPJournal of immunology (Baltimore, Md. : 1950)Human intestinal intraepithelial lymphocytes are derived from a limited number of T cell clones that utilize multiple V beta T cell receptor genes. J Immunol. 1993 Jun 01; 150(11):5144-53.J Immunol1993-06-01T00:00:001993Human intestinal intraepithelial lymphocytes are derived from a limited number of T cell clones that utilize multiple V beta T cell receptor genes.11358978Exley MA, Bigley NJ, Cheng O, Tahir SM, Smiley ST, Carter QL, Stills HF, Grusby MJ, Koezuka Y, Taniguchi M, Balk SPJournal of leukocyte biologyCD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leukoc Biol. 2001 May; 69(5):713-8.J Leukoc Biol2001-05-01T00:00:002001CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus.12368486Boyson JE, Rybalov B, Koopman LA, Exley M, Balk SP, Racke FK, Schatz F, Masch R, Wilson SB, Strominger JLProceedings of the National Academy of Sciences of the United States of AmericaCD1d and invariant NKT cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13741-6.Proc Natl Acad Sci U S A2002-10-04T00:00:002002CD1d and invariant NKT cells at the human maternal-fetal interface.14755679Taplin ME, Balk SPJournal of cellular biochemistryAndrogen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem. 2004 Feb 15; 91(3):483-90.J Cell Biochem2004-02-15T00:00:002004Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.16236129Sonoda KH, Sakamoto T, Qiao H, Hisatomi T, Oshima T, Tsutsumi-Miyahara C, Exley M, Balk SP, Taniguchi M, Ishibashi TImmunologyThe analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation. Immunology. 2005 Nov; 116(3):390-9.Immunology2005-11-01T00:00:002005The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation.7508419Canchis PW, Bhan AK, Landau SB, Yang L, Balk SP, Blumberg RSImmunologyTissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology. 1993 Dec; 80(4):561-5.Immunology1993-12-01T00:00:001993Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d.16809320Ilyinskii PO, Wang R, Balk SP, Exley MAJournal of virologyCD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo. J Virol. 2006 Jul; 80(14):7146-58.J Virol2006-07-01T00:00:002006CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.16877366Yuan X, Li T, Wang H, Zhang T, Barua M, Borgesi RA, Bubley GJ, Lu ML, Balk SPThe American journal of pathologyAndrogen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol. 2006 Aug; 169(2):682-96.Am J Pathol2006-08-01T00:00:002006Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.17062661van der Vliet HJ, Balk SP, Exley MAClinical cancer research : an official journal of the American Association for Cancer ResearchNatural killer T cell-based cancer immunotherapy. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):5921-3.Clin Cancer Res2006-10-15T00:00:002006Natural killer T cell-based cancer immunotherapy.18399827Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SPBJU internationalA phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9.BJU Int2008-05-01T00:00:002008A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.18432899Exley MA, Balk SP, Wilson SBCurrent protocols in immunologyIsolation and functional use of human NK T cells. Curr Protoc Immunol. 2003 Feb; Chapter 14:Unit 14.11.Curr Protoc Immunol2003-02-01T00:00:002003Isolation and functional use of human NK T cells.2477705Porcelli S, Brenner MB, Greenstein JL, Balk SP, Terhorst C, Bleicher PANatureRecognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes. Nature. 1989 Oct 05; 341(6241):447-50.Nature1989-10-05T00:00:001989Recognition of cluster of differentiation 1 antigens by human CD4-CD8-cytolytic T lymphocytes.22139837Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan XThe Journal of biological chemistryAndrogen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem. 2012 Jan 13; 287(3):2090-8.J Biol Chem2011-12-02T00:00:002011Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.Authorship 1118905230537509Russo JW, Balk SPCancer cellInitiation and Evolution of Early Onset Prostate Cancer. Cancer Cell. 2018 12 10; 34(6):874-876.Cancer Cell2018-12-10T00:00:002018Initiation and Evolution of Early Onset Prostate Cancer.7723794Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SPThe New England journal of medicineMutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25; 332(21):1393-8.N Engl J Med1995-05-25T00:00:001995Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.11773441Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SPMolecular endocrinology (Baltimore, Md.)AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002 Jan; 16(1):85-99.Mol Endocrinol2002-01-01T00:00:002002AR and ER interaction with a p21-activated kinase (PAK6).18493987Exley MA, Hou R, Shaulov A, Tonti E, Dellabona P, Casorati G, Akbari O, Akman HO, Greenfield EA, Gumperz JE, Boyson JE, Balk SP, Wilson SBEuropean journal of immunologySelective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol. 2008 Jun; 38(6):1756-66.Eur J Immunol2008-06-01T00:00:002008Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop.Authorship 11350072030773341Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown MCancer cellARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 03 18; 35(3):401-413.e6.Cancer Cell2019-02-14T00:00:002019ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.D018949Chemicals & Drugs974350.789195Antigens, CD1Authorship 1457351Authorship 11454033Authorship 11461761330932413Poluben L, Bryke CR, Hsu Y, Shumeiko O, Neumerzhitska L, Klimuk B, Rybchenko L, Klymenko S, Balk SP, Fraenkel PGExperimental oncologyCopy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis. Exp Oncol. 2019 Mar; 41(1):53-56.Exp Oncol2019-03-01T00:00:002019Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis.30890759Alsinnawi M, Zhang A, Bianchi-Frias D, Burns J, Cho E, Zhang X, Sowalsky A, Ye H, Slee AE, True L, Porter C, Taplin ME, Balk S, Nelson PS, Montgomery RB, Mostaghel EAProstate cancer and prostatic diseasesAssociation of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate Cancer Prostatic Dis. 2019 12; 22(4):560-568.Prostate Cancer Prostatic Dis2019-03-19T00:00:002019Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.30893145Einstein DJ, Arai S, Balk SPCurrent opinion in oncologyTargeting the androgen receptor and overcoming resistance in prostate cancer. Curr Opin Oncol. 2019 05; 31(3):175-182.Curr Opin Oncol2019-05-01T00:00:002019Targeting the androgen receptor and overcoming resistance in prostate cancer.D000728Chemicals & Drugs48212700.563055AndrogensD011944Chemicals & Drugs35710490.613193Receptors, AndrogenD059002Chemicals & Drugs531120.91104Androgen Receptor AntagonistsD011471Disorders1451109990.194321Prostatic NeoplasmsEmeritusMedicineRadiation OncologyGastroenterologyHematology/OncologyOncologyBeth Israel Deaconess Medical CenterBrigham and Women's HospitalDana-Farber Cancer InstitutePLN1PaulNguyenPaul Linh Nguyen, M.D.42.33510370000000-71.106164900000003917Nguyen, PaulProfessor of Radiation OncologyAVD2AnthonyD'AmicoAnthony V. D'Amico, M.D., Ph.D.42.33510370000000-71.1061649000000046434D'Amico, AnthonyProfessor of Radiation Oncology11266selected publications13.2430.00221889822research areas4.259280.00683741118coauthor of222.04431.112960similar toDS182DinaStroopinskyDina Stroopinsky, Ph.D.42.34022770000000-71.1058540000000088960Stroopinsky, DinaAssistant Professor of MedicineGJB6GlennBubleyGlenn J. Bubley, M.D.42.34022770000000-71.1058540000000015456Bubley, GlennAssociate Professor of MedicineAuthorship 1323811MT54Mary-EllenTaplinMary-Ellen Taplin, M.D.42.33789600000000-71.1072493000000044971Taplin, Mary-EllenProfessor of MedicineXY6XinYuanXin Yuan, D.Sc., M.D.42.33849900000000-71.1044600000000080347Yuan, XinAssistant Professor of MedicineGMW5GerburgWulfGerburg Wulf, M.D.42.34022770000000-71.1058540000000052689Wulf, GerburgAssociate Professor of MedicinePWK1PhilipKantoffPhilip Kantoff, M.D.42.33789600000000-71.1072493000000015015Kantoff, PhilipJerome and Nancy Kohlberg Professor of Medicine, EmeritusRS1RalphScullyRalph Scully, M.B.,B.S., Ph.D.42.34022770000000-71.1058540000000065657Scully, RalphProfessor of MedicineVAB1VassilikiBoussiotisVassiliki A. Boussiotis, M.D., Ph.D.42.34022770000000-71.1058540000000033563Boussiotis, VassilikiProfessor of MedicineRSB6RichardBlumbergRichard Steven Blumberg, M.D.42.33510370000000-71.106164900000005354Blumberg, RichardProfessor of MedicineAuthorship 1170938931302152Patterson JC, Joughin BA, Prota AE, Mühlethaler T, Jonas OH, Whitman MA, Varmeh S, Chen S, Balk SP, Steinmetz MO, Lauffenburger DA, Yaffe MBCell systemsVISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells. Cell Syst. 2019 07 24; 9(1):74-92.e8.Cell Syst2019-07-10T00:00:002019VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.Authorship 1453937Authorship 1182474731444154Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai CCancer researchZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer Res. 2019 10 15; 79(20):5260-5271.Cancer Res2019-08-23T00:00:002019ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.Authorship 11907801831528835Hennigan ST, Trostel SY, Terrigino NT, Voznesensky OS, Schaefer RJ, Whitlock NC, Wilkinson S, Carrabba NV, Atway R, Shema S, Lake R, Sweet AR, Einstein DJ, Karzai F, Gulley JL, Chang P, Bubley GJ, Balk SP, Ye H, Sowalsky AGJCO precision oncologyLow Abundance of Circulating Tumor DNA in Localized Prostate Cancer. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-09-09T00:00:002019Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer.Authorship 1200583331676563Russo JW, Nouri M, Balk SPCancer discoveryAndrogen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1. Cancer Discov. 2019 11; 9(11):1490-1492.Cancer Discov2019-11-01T00:00:002019Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1.Authorship 12043269true1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Jerome and Nancy Kohlberg Professor of Medicine, EmeritusJerome and Nancy Kohlberg Professor of Medicine, Emeritustrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Professor of MedicineProfessor of MedicineAuthorship 1266909true1Professor of Radiation OncologyProfessor of Radiation OncologyAuthorship 1200167Authorship 1215116Authorship 12313091132127357Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KWCancer researchATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100.Cancer Res2020-03-03T00:00:002020ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.Authorship 1795885Authorship 1843576Authorship 125220814Authorship 1252859632478682Gjyrezi A, Xie F, Voznesensky O, Khanna P, Calagua C, Bai Y, Kung J, Wu J, Corey E, Montgomery B, Mace S, Gianolio DA, Bubley GJ, Balk SP, Giannakakou P, Bhatt RSThe Journal of clinical investigationTaxane resistance in prostate cancer is mediated by decreased drug-target engagement. J Clin Invest. 2020 06 01; 130(6):3287-3298.J Clin Invest2020-06-01T00:00:002020Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.32484436Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SPeLifeMARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Elife. 2020 06 02; 9.Elife2020-06-02T00:00:002020MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.Authorship 14351917Authorship 12695782232679108Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CLCancer cellTumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 08 10; 38(2):279-296.e9.Cancer Cell2020-07-16T00:00:002020Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.Authorship 12815882032868907Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai CNature geneticsChromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020 10; 52(10):1011-1017.Nat Genet2020-08-31T00:00:002020Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.Authorship 12876011232913968Han GC, Hwang J, Wankowicz SAM, Zhang Z, Liu D, Cibulskis C, Gaviola GC, Ghazikhanian V, McKay RR, Bubley GJ, Carter SL, Balk SP, Hahn WC, Taplin ME, Van Allen EMJCO precision oncologyGenomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2017; 1.JCO Precis Oncol2017-12-11T00:00:002017Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.Authorship 1374553Authorship 12943141933037017Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah KClinical cancer research : an official journal of the American Association for Cancer ResearchComparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 01 01; 27(1):320-329.Clin Cancer Res2020-10-09T00:00:002020Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.Authorship 12964963633086052Richters A, Doyle SK, Freeman DB, Lee C, Leifer BS, Jagannathan S, Kabinger F, Koren JV, Struntz NB, Urgiles J, Stagg RA, Curtin BH, Chatterjee D, Mathea S, Mikochik PJ, Hopkins TD, Gao H, Branch JR, Xin H, Westover L, Bignan GC, Rupnow BA, Karlin KL, Olson CM, Westbrook TF, Vacca J, Wilfong CM, Trotter BW, Saffran DC, Bischofberger N, Knapp S, Russo JW, Hickson I, Bischoff JR, Gottardis MM, Balk SP, Lin CY, Pop MS, Koehler ANCell chemical biologyModulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chem Biol. 2021 02 18; 28(2):134-147.e14.Cell Chem Biol2020-10-20T00:00:002020Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors.true1Assistant Professor of MedicineAssistant Professor of MedicineAuthorship 1458082Authorship 2151248Authorship 225834433664492He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EMNature medicineTranscriptional mediators of treatment resistance in lethal prostate cancer. Nat Med. 2021 03; 27(3):426-433.Nat Med2021-03-04T00:00:002021Transcriptional mediators of treatment resistance in lethal prostate cancer.Authorship 133587031Authorship 1654571Authorship 13513683333899001Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, Qiu X, Cañadas I, Roehle K, Heckler M, Calagua C, Ye H, Pantelidou C, Galbo P, Panja S, Mitrofanova A, Wilkinson S, Whitlock NC, Trostel SY, Hamid AA, Kibel AS, Barbie DA, Choudhury AD, Pomerantz MM, Sweeney CJ, Long HW, Einstein DJ, Shapiro GI, Dougan SK, Sowalsky AG, He HH, Freedman ML, Balk SP, Loda M, Labbé DP, Olson BM, Ellis LNature cancerEZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 04; 2(4):444-456.Nat Cancer2021-03-22T00:00:002021EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Authorship 154176102026-05-31BALK, STEVEN P.2021-06-01Prostate Cancer Vulnerabilities to BH3 Mimetic DrugsR01CA262536Principal InvestigatorAuthorship 1721056Authorship 13698641634168052Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJClinical cancer research : an official journal of the American Association for Cancer ResearchA Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clin Cancer Res. 2021 09 01; 27(17):4836-4847.Clin Cancer Res2021-06-24T00:00:002021A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Authorship 13748621434256096Liang J, Wang L, Poluben L, Nouri M, Arai S, Xie L, Voznesensky OS, Cato L, Yuan X, Russo JW, Long HW, Brown M, Chen S, Balk SPCancer lettersAndrogen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells. Cancer Lett. 2021 10 28; 519:172-184.Cancer Lett2021-07-10T00:00:002021Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.Authorship 1964441Authorship 1385854934407973Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT, Cheng HH, Kantoff PW, Balk SP, Taplin ME, Sharifi N, Matsumoto AM, Nelson PS, Montgomery RBClinical cancer research : an official journal of the American Association for Cancer ResearchCirculating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 11 01; 27(21):6001-6011.Clin Cancer Res2021-08-18T00:00:002021Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Authorship 13885821034439209Francini E, Ou FS, Rhoades J, Wolfe EG, O'Connor EP, Ha G, Gydush G, Kelleher KM, Bhatt RS, Balk SP, Sweeney CJ, Adalsteinsson VA, Taplin ME, Choudhury ADCancersCirculating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021 Aug 12; 13(16).Cancers (Basel)2021-08-12T00:00:002021Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.Authorship 177073Authorship 13947821734496240Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, Brown M, Balk SP, Getz G, Taplin ME, Van Allen EMCell reportsMolecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021 09 07; 36(10):109665.Cell Rep2021-09-07T00:00:002021Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.Authorship 1400022934568716Einstein DJ, Arai S, Calagua C, Xie F, Voznesensky O, Capaldo BJ, Luffman C, Hecht JL, Balk SP, Sowalsky AG, Russo JWJCO precision oncologyMetastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors. JCO Precis Oncol. 2021; 5.JCO Precis Oncol2021-09-16T00:00:002021Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors.Authorship 2258976Authorship 14196621634911936Guo H, Wu Y, Nouri M, Spisak S, Russo JW, Sowalsky AG, Pomerantz MM, Wei Z, Korthauer K, Seo JH, Wang L, Arai S, Freedman ML, He HH, Chen S, Balk SPNature communicationsAndrogen receptor and MYC equilibration centralizes on developmental super-enhancer. Nat Commun. 2021 12 15; 12(1):7308.Nat Commun2021-12-15T00:00:002021Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.35031563Liao Y, Chen CH, Xiao T, de la Peña Avalos B, Dray EV, Cai C, Gao S, Shah N, Zhang Z, Feit A, Xue P, Liu Z, Yang M, Lee JH, Xu H, Li W, Mei S, Pierre RS, Shu S, Fei T, Duarte M, Zhao J, Bradner JE, Polyak K, Kantoff PW, Long H, Balk SP, Liu XS, Brown M, Xu KProceedings of the National Academy of Sciences of the United States of AmericaInhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proc Natl Acad Sci U S A. 2022 01 18; 119(3).Proc Natl Acad Sci U S A2022-01-18T00:00:002022Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.35008216Westaby D, Jimenez-Vacas JM, Padilha A, Varkaris A, Balk SP, de Bono JS, Sharp ACancersTargeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. Cancers (Basel). 2021 Dec 23; 14(1).Cancers (Basel)2021-12-23T00:00:002021Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.Authorship 142670527Authorship 14253215Authorship 14285681635082166Dong X, Xue H, Mo F, Lin YY, Lin D, Wong NKY, Sun Y, Wilkinson S, Ku AT, Hao J, Ci X, Wu R, Haegert A, Silver R, Taplin ME, Balk SP, Alumkal JJ, Sowalsky AG, Gleave M, Collins C, Wang YMolecular cancer research : MCRModeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications. Mol Cancer Res. 2022 05 04; 20(5):782-793.Mol Cancer Res2022-05-04T00:00:002022Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.Authorship 143111817Authorship 14301561435121110Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai CMolecular therapy : the journal of the American Society of Gene TherapyExploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther. 2022 04 06; 30(4):1628-1644.Mol Ther2022-02-02T00:00:002022Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.35131873Ma F, Arai S, Wang K, Calagua C, Yuan AR, Poluben L, Gu Z, Russo JW, Einstein DJ, Ye H, He MX, Liu Y, Van Allen E, Sowalsky AG, Bhasin MK, Yuan X, Balk SPCancer researchAutocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer. Cancer Res. 2022 04 15; 82(8):1518-1533.Cancer Res2022-04-15T00:00:002022Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer.Authorship 2463123Authorship 143527210Authorship 14390354Authorship 1436289335201849Varkaris A, Stevens J, Ono Y, Balk SP, Bellmunt JJCO precision oncologyA Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide. JCO Precis Oncol. 2022 02; 6:e2100091.JCO Precis Oncol2022-02-01T00:00:002022A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.35333400Mendes AA, Lu J, Kaur HB, Zheng SL, Xu J, Hicks J, Weiner AB, Schaeffer EM, Ross AE, Balk SP, Taplin ME, Lack NA, Tekoglu E, Maynard JP, De Marzo AM, Antonarakis ES, Sfanos KS, Joshu CE, Shenderov E, Lotan TLCancerAssociation of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 2022 06 15; 128(12):2269-2280.Cancer2022-03-25T00:00:002022Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.35254710Sentana-Lledo D, Sartor O, Balk SP, Einstein DJThe ProstateImmune mechanisms behind prostate cancer in men of African ancestry: A review. Prostate. 2022 06; 82(8):883-893.Prostate2022-03-07T00:00:002022Immune mechanisms behind prostate cancer in men of African ancestry: A review.Authorship 14473661135523889Varghese B, Lynch L, Vriend LE, Draganov D, Clark JM, Kissick HT, Varghese S, Sanda MG, Dranoff G, Arredouani MS, Balk SP, Exley MACancer immunology, immunotherapy : CIIInvariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model. Cancer Immunol Immunother. 2022 Dec; 71(12):2943-2955.Cancer Immunol Immunother2022-05-06T00:00:002022Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.Authorship 3009183Authorship 3586691Authorship 3744436Authorship 14587212535695870Sowalsky AG, Figueiredo I, Lis RT, Coleman I, Gurel B, Bogdan D, Yuan W, Russo JW, Bright JR, Whitlock NC, Trostel SY, Ku AT, Patel RA, True LD, Welti J, Jimenez-Vacas JM, Rodrigues DN, Riisnaes R, Neeb A, Sprenger CT, Swain A, Wilkinson S, Karzai F, Dahut WL, Balk SP, Corey E, Nelson PS, Haffner MC, Plymate SR, de Bono JS, Sharp AClinical cancer research : an official journal of the American Association for Cancer ResearchAssessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2022 08 15; 28(16):3509-3525.Clin Cancer Res2022-08-15T00:00:002022Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Authorship 4430098Authorship 4468492Authorship 450506723752196Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SPOncogeneAndrogen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 2014 May 29; 33(22):2815-25.Oncogene2013-06-10T00:00:002013Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.Authorship 15063771836413141Patterson JC, Varkaris A, Croucher PJP, Ridinger M, Dalrymple S, Nouri M, Xie F, Varmeh S, Jonas O, Whitman MA, Chen S, Rashed S, Makusha L, Luo J, Isaacs JT, Erlander MG, Einstein DJ, Balk SP, Yaffe MBCancer researchPlk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Res. 2023 01 18; 83(2):219-238.Cancer Res2023-01-18T00:00:002023Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.Authorship 15172251136622276Wang K, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, Voznesensky O, Xie F, Zhang X, Yuan X, Balk SPCancer researchWNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Res. 2023 04 04; 83(7):1016-1030.Cancer Res2023-04-04T00:00:002023WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.Authorship 1790213Authorship 1531801836877164Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai CCancer researchLSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Res. 2023 05 15; 83(10):1684-1698.Cancer Res2023-05-15T00:00:002023LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Authorship 2071432Authorship 205608837139568Iyer HS, Vaselkiv JB, Stopsack KH, Roscoe C, DeVille NV, Zhang Y, Penney KL, Balk SP, Fiorentino M, Hart JE, James P, De Vivo I, Mucci LA, Laden F, Rebbeck TRAmerican journal of epidemiologyInfluence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals. Am J Epidemiol. 2023 09 01; 192(9):1485-1498.Am J Epidemiol2023-09-01T00:00:002023Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals.Authorship 15579608Authorship 3287765Authorship 15914791437663929Besschetnova A, Han W, Liu M, Gao Y, Li M, Wang Z, Labaf M, Patalano S, Venkataramani K, Muriph RE, Macoska JA, Siegfried KR, Evans J, Balk SP, Gao S, Han D, Cai CCancer research communicationsDemethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression. Cancer Res Commun. 2023 08; 3(8):1716-1730.Cancer Res Commun2023-08-31T00:00:002023Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.true1Professor of Radiation OncologyProfessor of Radiation OncologyAuthorship 49923472028-08-31BELTRAN, HIMISHA2023-09-01DF/HCC Prostate SPOREP50CA2723902028-05-31BALK, STEVEN P.2023-06-01WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate CancerR01CA272934Co-Principal InvestigatorPrincipal InvestigatorAuthorship 16189291038182874Arai S, Gao Y, Yu Z, Xie L, Wang L, Zhang T, Nouri M, Chen S, Asara JM, Balk SPCommunications biologyA carboxy-terminal ubiquitylation site regulates androgen receptor activity. Commun Biol. 2024 01 05; 7(1):25.Commun Biol2024-01-05T00:00:002024A carboxy-terminal ubiquitylation site regulates androgen receptor activity.Authorship 16232111838260576Poluben L, Nouri M, Liang J, Varkaris A, Ersoy-Fazlioglu B, Voznesensky O, Lee II, Qiu X, Cato L, Seo JH, Freedman ML, Sowalsky AG, Lack NA, Corey E, Nelson PS, Brown M, Long HW, Balk SP, Russo JWbioRxiv : the preprint server for biologyIncreased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer. bioRxiv. 2024 Jan 12.bioRxiv2024-01-12T00:00:002024Increased chromatin accessibility drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer.Authorship 1658926Authorship 28916011Authorship 3328106Authorship 4625074Authorship 2582521Authorship 3153099Authorship 3254255Authorship 3323141Authorship 4961955Authorship 645009823716717Chen S, Jiang X, Gewinner CA, Asara JM, Simon NI, Cai C, Cantley LC, Balk SPScience signalingTyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal. 2013 May 28; 6(277):ra40.Sci Signal2013-05-28T00:00:002013Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.Authorship 54555Authorship 92374Authorship 22354810Authorship 3325074Authorship 344713Authorship 3503973Authorship 692945923851165Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin ME, Balk S, Ellis W, True L, Vessella R, Montgomery B, Blair IA, Penning TMThe Journal of steroid biochemistry and molecular biologyDevelopment, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol. 2013 Nov; 138:281-9.J Steroid Biochem Mol Biol2013-07-10T00:00:002013Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.Authorship 3657867Authorship 2169774Authorship 703855624323034Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery BJournal of clinical oncology : official journal of the American Society of Clinical OncologyTargeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.J Clin Oncol2013-12-09T00:00:002013Targeted androgen pathway suppression in localized prostate cancer: a pilot study.Authorship 2392396Authorship 261009224449822Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchRapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1590-600.Clin Cancer Res2014-01-21T00:00:002014Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.Authorship 3139584Authorship 3847832Authorship 2926812Authorship 3065311Authorship 20282010Authorship 7134258Authorship 7191875Authorship 7212861623594111Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NSACS chemical biologyDiscovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol. 2013 Jul 19; 8(7):1423-8.ACS Chem Biol2013-04-26T00:00:002013Discovery of a selective irreversible BMX inhibitor for prostate cancer.24139549Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor OCancer treatment reviewsCastration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014 Apr; 40(3):426-33.Cancer Treat Rev2013-09-14T00:00:002013Castration-resistant prostate cancer: adaptive responses in the androgen axis.Authorship 2788291Authorship 2199876Authorship 7311617Authorship 7298841123770851Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PWOncogeneMiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014 May 22; 33(21):2790-800.Oncogene2013-06-17T00:00:002013MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.24778216Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PWProceedings of the National Academy of Sciences of the United States of AmericaEnhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7319-24.Proc Natl Acad Sci U S A2014-04-28T00:00:002014Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.Authorship 1804093Authorship 7330196Authorship 744087124759584Balk SPAsian journal of andrologyAndrogen receptor functions in prostate cancer development and progression. Asian J Androl. 2014 Jul-Aug; 16(4):561-4.Asian J Androl2014-07-01T00:00:002014Androgen receptor functions in prostate cancer development and progression.24874833Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchGaleterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014 Aug 01; 20(15):4075-85.Clin Cancer Res2014-05-29T00:00:002014Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.Authorship 4961339Authorship 7474763Authorship 7522606Authorship 750822424838891Chin YR, Yuan X, Balk SP, Toker ACancer discoveryPTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014 Aug; 4(8):942-55.Cancer Discov2014-05-16T00:00:002014PTEN-deficient tumors depend on AKT2 for maintenance and survival.25049428Porcelli S, Yockey CE, Brenner MB, Balk SPJournal of immunology (Baltimore, Md. : 1950)Pillars article: analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- a/ß T cells demonstrates preferential use of several Vß genes and an invariant TCR a chain. J. Exp. Med. 1993. 178: 1-16. J Immunol. 2014 Aug 01; 193(3):977-92.J Immunol2014-08-01T00:00:002014Pillars article: analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- a/ß T cells demonstrates preferential use of several Vß genes and an invariant TCR a chain. J. Exp. Med. 1993. 178: 1-16.25189356Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Balk SP, Li WMolecular cancer research : MCRWhole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer. Mol Cancer Res. 2015 Jan; 13(1):98-106.Mol Cancer Res2014-09-04T00:00:002014Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.Authorship 369751525320358Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin MEClinical cancer research : an official journal of the American Association for Cancer ResearchAbiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.Clin Cancer Res2014-10-15T00:00:002014Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.25091040McKay RR, Zukotynski KA, Werner L, Voznesensky O, Wu JS, Smith SE, Jiang Z, Melnick K, Yuan X, Kantoff PW, Montgomery B, Balk SP, Taplin MEProstate cancer and prostatic diseasesImaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):325-31.Prostate Cancer Prostatic Dis2014-08-05T00:00:002014Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.DJE18DavidEinsteinDavid Johnson Einstein, M.D.132809Einstein, DavidAssistant Professor of MedicineAuthorship 76925012Authorship 7703501625311217Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PWJournal of clinical oncology : official journal of the American Society of Clinical OncologyIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014 Nov 20; 32(33):3705-15.J Clin Oncol2014-10-13T00:00:002014Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Authorship 4996744Authorship 7755191625482560Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Schüle R, Liu XS, Brown M, Balk SPCell reportsLysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014 Dec 11; 9(5):1618-1627.Cell Rep2014-12-04T00:00:002014Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.Authorship 4957173Authorship 555660525580383Cai C, Yuan X, Balk SPTranslational andrology and urologyAndrogen receptor epigenetics. Transl Androl Urol. 2013 Sep 01; 2(3):148-157.Transl Androl Urol2013-09-01T00:00:002013Androgen receptor epigenetics.Authorship 730932Authorship 2631432Authorship 52466710Authorship 3999106Authorship 407444Authorship 3750261Authorship 4229766Authorship 3894445Authorship 4029627Authorship 4315185Authorship 4393625Authorship 1584032Authorship 3557817Authorship 4725305Authorship 5085855Authorship 22344417Authorship 52129510Authorship 554578425906751Sowalsky AG, Sager R, Schaefer RJ, Bratslavsky G, Pandolfi PP, Balk SP, Kotula LOncotargetLoss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget. 2015 May 20; 6(14):12383-91.Oncotarget2015-05-20T00:00:002015Loss of Wave1 gene defines a subtype of lethal prostate cancer.Authorship 225512Authorship 523124Authorship 1762355Authorship 168376Authorship 1771294Authorship 2276238Authorship 3153557Authorship 2454487Authorship 967135Authorship 1832584Authorship 705645Authorship 961998Authorship 785566Authorship 24640713Authorship 29007910Authorship 2410375Authorship 2725552Authorship 3355203Authorship 3445227Authorship 3029964Authorship 38686011Authorship 3959984Authorship 196806Authorship 2404111Authorship 2454623Authorship 3694462Authorship 3754907Authorship 4019274Authorship 2109858Authorship 2119567Authorship 4854915Authorship 5402495Authorship 2337358Authorship 3304834Authorship 7924236Authorship 7996793Authorship 80561411Authorship 80038612Authorship 79754716Authorship 7943305Authorship 790192725514466Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TMChemico-biological interactionsThe DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015 Jun 05; 234:332-8.Chem Biol Interact2014-12-13T00:00:002014The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.25808865Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PWCancer researchPLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res. 2015 May 15; 75(10):1944-8.Cancer Res2015-03-25T00:00:002015PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.25670076Plymate SR, Bhatt RS, Balk SPCancer cellTaxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2. Cancer Cell. 2015 Feb 09; 27(2):158-9.Cancer Cell2015-02-09T00:00:002015Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2.25132238Lu J, Lonergan PE, Nacusi LP, Wang L, Schmidt LJ, Sun Z, Van der Steen T, Boorjian SA, Kosari F, Vasmatzis G, Klee GG, Balk SP, Huang H, Wang C, Tindall DJThe Journal of urologyThe cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol. 2015 Feb; 193(2):690-8.J Urol2014-08-14T00:00:002014The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells.Authorship 3337914Authorship 2584935Authorship 2752614Authorship 37142920Authorship 3743318Authorship 39115012Authorship 4215652Authorship 4255010Authorship 4962662Authorship 543012Authorship 3069455Authorship 823938226181796Taplin ME, Balk SPJAMA oncologyHas the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer? JAMA Oncol. 2015 Aug; 1(5):577-9.JAMA Oncol2015-08-01T00:00:002015Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?Authorship 4345567Authorship 4830804Authorship 5424925Authorship 706937Authorship 853177Authorship 4498334Authorship 4828705Authorship 5194236Authorship 5621885Authorship 8627591026636645Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen SOncotargetProtein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. 2016 Jan 12; 7(2):1754-64.Oncotarget2016-01-12T00:00:002016Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation.Authorship 608543Authorship 392064Authorship 4137436Authorship 8799911127043282Ma F, Ye H, He HH, Gerrin SJ, Chen S, Tanenbaum BA, Cai C, Sowalsky AG, He L, Wang H, Balk SP, Yuan XThe Journal of clinical investigationSOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016 05 02; 126(5):1745-58.J Clin Invest2016-04-04T00:00:002016SOX9 drives WNT pathway activation in prostate cancer.Authorship 4363575Authorship 4453022Authorship 883856727225130Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi NNatureRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 05 26; 533(7604):547-51.Nature2016-05-26T00:00:002016Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.Authorship 5377594Authorship 5678455Authorship 86456132Assistant Professor1Associate Professor0Full ProfessorAuthorship 8934171526936914Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai CClinical cancer research : an official journal of the American Association for Cancer ResearchErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82.Clin Cancer Res2016-03-02T00:00:002016ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Authorship 761915Authorship 766761Authorship 895658327272561Gerrin SJ, Sowalsky AG, Balk SP, Ye HThe ProstateMutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma. Prostate. 2016 09; 76(13):1227-36.Prostate2016-06-08T00:00:002016Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.Authorship 914491Authorship 4824728Authorship 4866896Authorship 4882738Authorship 55424541999-05-31BALK, STEVEN P.1998-06-15IMMUNE REGULATION BY CD1D REACTIVE NKP-P1 T CELLSR21AI0429552008-06-30BALK, STEVEN P.2006-07-01HTS for Androgen Receptor Antagonists that Recruit NCoRR21NS0570512024-01-31BALK, STEVEN P.2013-05-24Androgen Receptor Action in Castration Resistant Prostate CancerP01CA1632272019-06-30BELTRAN, HIMISHA2001-04-01DF/HCC SPORE in Prostate CancerP50CA0903811991-06-30BALK, STEVEN P.1987-07-08ISOLATION OF A HUMAN HOMOLOGUE OF THE MURINE LY-6 SYSTEMK11CA0013102004-06-30BALK, STEVEN P.1999-07-01IMMUNE REGULATION BY CD1D REACTIVE NKR-P1 T CELLSR01AI0429552007-05-31BALK, STEVEN P.2002-07-01AR Transgene Model of Prostate Intraepithelial NeoplasiaR01DK0610472012-06-30BALK, STEVEN P.2000-04-01Training Grant in Cancer BiologyT32CA0811562019-04-30BALK, STEVEN P2014-05-13SOX9 Mediation of AR and ERG Driven Prostate CancerR01CA1683932000-11-30BALK, STEVEN P.1996-04-01AR MUTATIONS IN ANDROGEN-INDEPENDENT PROSTATE CANCERR01CA0656472003-08-31BALK, STEVEN P.1993-05-01FUNCTION OF HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTESR01AI0339112013-04-30BALK, STEVEN P.2007-05-01Targeting AR-NCoR Interaction in Prostate CancerR01CA1118032004-06-30BALK, STEVEN P.2001-08-10Invariant NKT Cells For Phase 1 Cancer TrialsR21CA089611Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 673907Authorship 809527Authorship 4042788Authorship 92482912Authorship 922834327760327Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai CCell reportsAndrogen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016 10 18; 17(4):966-976.Cell Rep2016-10-18T00:00:002016Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.Authorship 5601681Authorship 93060236893854Mescher MF, Jose MJ, Balk SPNatureActin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells. Nature. 1981 Jan 15; 289(5794):139-44.Nature1981-01-15T00:00:001981Actin-containing matrix associated with the plasma membrane of murine tumour and lymphoid cells.Authorship 2149105Authorship 3361029Authorship 94354415Authorship 942340827953925Hayes JH, Oh WK, Kantoff PW, Manola JB, Smith MR, Gelmann EP, Bubley G, Balk SP, Taplin MJournal of clinical oncology : official journal of the American Society of Clinical OncologyMifepristone (RU-486) in androgen independent prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14508.J Clin Oncol2006-06-20T00:00:002006Mifepristone (RU-486) in androgen independent prostate cancer.27683182McKay RR, Werner L, Mostaghel EA, Lis R, Voznesensky O, Zhang Z, Marck BT, Matsumoto AM, Domachevsky L, Zukotynski KA, Bhasin M, Bubley GJ, Montgomery B, Kantoff PW, Balk SP, Taplin MEClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):935-945.Clin Cancer Res2016-09-28T00:00:002016A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.Authorship 9474572Authorship 9475051328059730Kelly K, Balk SPScience (New York, N.Y.)Reprogramming to resist. Science. 2017 01 06; 355(6320):29-30.Science2017-01-06T00:00:002017Reprogramming to resist.28062857Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SPNucleic acids researchPositive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017 04 20; 45(7):3738-3751.Nucleic Acids Res2017-04-20T00:00:002017Positive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.Authorship 4572273Authorship 4898164Authorship 566182Authorship 95522416Authorship 953790628139868DeLeonardis K, Sedgwick K, Voznesensky O, Matloff E, Hofstatter E, Balk S, Tung NThe breast journalChallenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. Breast J. 2017 Jul; 23(4):461-464.Breast J2017-01-31T00:00:002017Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.28151719Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin DW, Sanda M, Novotny W, Wu K, Kantoff PW, Marck BT, Plymate S, Balk SP, Nelson PS, Matsumoto AM, Lis RT, Kibel A, Haas GP, Krivoshik A, Hannah A, Taplin MEClinical cancer research : an official journal of the American Association for Cancer ResearchNeoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.Clin Cancer Res2016-11-09T00:00:002016Neoadjuvant Enzalutamide Prior to Prostatectomy.Authorship 9575761828193627Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchAdoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15; 23(14):3510-3519.Clin Cancer Res2017-02-13T00:00:002017Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.Authorship 9340548778025Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SPImmunologyEvidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7.Immunology1996-03-01T00:00:001996Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression.8773507Bubley GJ, Balk SPHematology/oncology clinics of North AmericaTreatment of metastatic prostate cancer. Lessons from the androgen receptor. Hematol Oncol Clin North Am. 1996 Jun; 10(3):713-25.Hematol Oncol Clin North Am1996-06-01T00:00:001996Treatment of metastatic prostate cancer. Lessons from the androgen receptor.8760056Colgan SP, Morales VM, Madara JL, Polischuk JE, Balk SP, Blumberg RSThe American journal of physiologyIFN-gamma modulates CD1d surface expression on intestinal epithelia. Am J Physiol. 1996 Jul; 271(1 Pt 1):C276-83.Am J Physiol1996-07-01T00:00:001996IFN-gamma modulates CD1d surface expression on intestinal epithelia.8847079Blumberg RS, Gerdes D, Chott A, Porcelli SA, Balk SPImmunological reviewsStructure and function of the CD1 family of MHC-like cell surface proteins. Immunol Rev. 1995 Oct; 147:5-29.Immunol Rev1995-10-01T00:00:001995Structure and function of the CD1 family of MHC-like cell surface proteins.8816432Probert CS, Chott A, Turner JR, Saubermann LJ, Stevens AC, Bodinaku K, Elson CO, Balk SP, Blumberg RSJournal of immunology (Baltimore, Md. : 1950)Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol. 1996 Oct 01; 157(7):3183-91.J Immunol1996-10-01T00:00:001996Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease.9276515Blumberg RS, Colgan SP, Balk SPClinical and experimental immunologyCD1d: outside-in antigen presentation in the intestinal epithelium? Clin Exp Immunol. 1997 Aug; 109(2):223-5.Clin Exp Immunol1997-08-01T00:00:001997CD1d: outside-in antigen presentation in the intestinal epithelium?10221650Somnay-Wadgaonkar K, Nusrat A, Kim HS, Canchis WP, Balk SP, Colgan SP, Blumberg RSInternational immunologyImmunolocalization of CD1d in human intestinal epithelial cells and identification of a beta2-microglobulin-associated form. Int Immunol. 1999 Mar; 11(3):383-92.Int Immunol1999-03-01T00:00:001999Immunolocalization of CD1d in human intestinal epithelial cells and identification of a beta2-microglobulin-associated form.11123275Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein JJournal of immunology (Baltimore, Md. : 1950)NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol. 2001 Jan 01; 166(1):42-50.J Immunol2001-01-01T00:00:002001NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance.1700477Bleicher PA, Balk SP, Hagen SJ, Blumberg RS, Flotte TJ, Terhorst CScience (New York, N.Y.)Expression of murine CD1 on gastrointestinal epithelium. Science. 1990 Nov 02; 250(4981):679-82.Science1990-11-02T00:00:001990Expression of murine CD1 on gastrointestinal epithelium.1716785Balk SP, Ebert EC, Blumenthal RL, McDermott FV, Wucherpfennig KW, Landau SB, Blumberg RSScience (New York, N.Y.)Oligoclonal expansion and CD1 recognition by human intestinal intraepithelial lymphocytes. Science. 1991 Sep 20; 253(5026):1411-5.Science1991-09-20T00:00:001991Oligoclonal expansion and CD1 recognition by human intestinal intraepithelial lymphocytes.9400459Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJThe Journal of urologyHigh dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol. 1998 Jan; 159(1):149-53.J Urol1998-01-01T00:00:001998High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.8824574Porcelli S, Gerdes D, Fertig AM, Balk SPHuman immunologyHuman T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression. Hum Immunol. 1996 Jun-Jul; 48(1-2):63-7.Hum Immunol1996-06-01T00:00:001996Human T cells expressing an invariant V alpha 24-J alpha Q TCR alpha are CD4- and heterogeneous with respect to TCR beta expression.10092605Kim HS, Garcia J, Exley M, Johnson KW, Balk SP, Blumberg RSThe Journal of biological chemistryBiochemical characterization of CD1d expression in the absence of beta2-microglobulin. J Biol Chem. 1999 Apr 02; 274(14):9289-95.J Biol Chem1999-04-02T00:00:001999Biochemical characterization of CD1d expression in the absence of beta2-microglobulin.Authorship 96068412Authorship 9658921027948754Taplin M, Ko Y, Regan MM, Beer TM, Carducci MA, Mathew P, Bubley G, Oh WK, Kantoff PW, Balk SPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC). J Clin Oncol. 2008 May 20; 26(15_suppl):5068.J Clin Oncol2008-05-20T00:00:002008Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).28119368Sowalsky AG, Kissick HT, Gerrin SJ, Schaefer RJ, Xia Z, Russo JW, Arredouani MS, Bubley GJ, Sanda MG, Li W, Ye H, Balk SPClinical cancer research : an official journal of the American Association for Cancer ResearchGleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res. 2017 Jul 15; 23(14):3823-3833.Clin Cancer Res2017-01-24T00:00:002017Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.11238626Wang B, Chun T, Rulifson IC, Exley M, Balk SP, Wang CRJournal of immunology (Baltimore, Md. : 1950)Human CD1d functions as a transplantation antigen and a restriction element in mice. J Immunol. 2001 Mar 15; 166(6):3829-36.J Immunol2001-03-15T00:00:002001Human CD1d functions as a transplantation antigen and a restriction element in mice.Authorship 9700542828274958Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LCCancer discoveryCabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765.Cancer Discov2017-03-08T00:00:002017Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.10363963Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SPCancer researchSelection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999 Jun 01; 59(11):2511-5.Cancer Res1999-06-01T00:00:001999Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.9029136Probert CS, Christ AD, Saubermann LJ, Turner JR, Chott A, Carr-Locke D, Balk SP, Blumberg RSJournal of immunology (Baltimore, Md. : 1950)Analysis of human common bile duct-associated T cells: evidence for oligoclonality, T cell clonal persistence, and epithelial cell recognition. J Immunol. 1997 Feb 15; 158(4):1941-8.J Immunol1997-02-15T00:00:001997Analysis of human common bile duct-associated T cells: evidence for oligoclonality, T cell clonal persistence, and epithelial cell recognition.10332632Landau SB, Probert CS, Stevens CA, Balk SP, Blumberg RSJournal of clinical & laboratory immunologyOver-utilization of the J delta 3 gene-segment in Crohn's disease. J Clin Lab Immunol. 1996; 48(1):33-44.J Clin Lab Immunol1996-01-01T00:00:001996Over-utilization of the J delta 3 gene-segment in Crohn's disease.10440698Sun Z, Pan J, Hope WX, Cohen SN, Balk SPCancerTumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer. 1999 Aug 15; 86(4):689-96.Cancer1999-08-15T00:00:001999Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300.1532439Davis TH, Morton CC, Miller-Cassman R, Balk SP, Kadin METhe New England journal of medicineHodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med. 1992 Apr 23; 326(17):1115-22.N Engl J Med1992-04-23T00:00:001992Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone.11585838Yuan X, Lu ML, Li T, Balk SPThe Journal of biological chemistrySRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem. 2001 Dec 07; 276(49):46647-54.J Biol Chem2001-10-03T00:00:002001SRY interacts with and negatively regulates androgen receptor transcriptional activity.18339840Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP, Yuan XCancer researchSOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 2008 Mar 15; 68(6):1625-30.Cancer Res2008-03-15T00:00:002008SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion.19491261Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SPCancer researchAndrogen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009 Jun 15; 69(12):5202-9.Cancer Res2009-06-02T00:00:002009Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.12015321Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SPThe Journal of biological chemistryBicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem. 2002 Jul 19; 277(29):26321-6.J Biol Chem2002-05-15T00:00:002002Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.14612401Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Jänne OA, Muratoglu S, Avantaggiati ML, Pestell RGMolecular and cellular biologyAcetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol. 2003 Dec; 23(23):8563-75.Mol Cell Biol2003-12-01T00:00:002003Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth.10514409Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SPThe American journal of pathologyTyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol. 1999 Oct; 155(4):1271-9.Am J Pathol1999-10-01T00:00:001999Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.11698421Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SPJournal of immunology (Baltimore, Md. : 1950)A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses. J Immunol. 2001 Nov 15; 167(10):5531-4.J Immunol2001-11-15T00:00:002001A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses.Authorship 9760821628389510Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RBClinical cancer research : an official journal of the American Association for Cancer ResearchAssociation of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4592-4601.Clin Cancer Res2017-04-07T00:00:002017Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.15550393Kaur R, Liu X, Gjoerup O, Zhang A, Yuan X, Balk SP, Schneider MC, Lu MLThe Journal of biological chemistryActivation of p21-activated kinase 6 by MAP kinase kinase 6 and p38 MAP kinase. J Biol Chem. 2005 Feb 04; 280(5):3323-30.J Biol Chem2004-11-18T00:00:002004Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38 MAP kinase.15810882Nieuwenhuis EE, Gillessen S, Scheper RJ, Exley MA, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Blumberg RS, Wilson SBExperimental dermatologyCD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp Dermatol. 2005 Apr; 14(4):250-8.Exp Dermatol2005-04-01T00:00:002005CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity.16885382Xu Y, Chen SY, Ross KN, Balk SPCancer researchAndrogens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. Cancer Res. 2006 Aug 01; 66(15):7783-92.Cancer Res2006-08-01T00:00:002006Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.16964290Cai C, Chen SY, Zheng Z, Omwancha J, Lin MF, Balk SP, Shemshedini LOncogeneAndrogen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene. 2007 Mar 08; 26(11):1606-15.Oncogene2006-09-11T00:00:002006Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.17218776Masiello D, Mohi MG, McKnight NC, Smith B, Neel BG, Balk SP, Bubley GJCancer biology & therapyCombining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther. 2007 Feb; 6(2):195-201.Cancer Biol Ther2007-02-07T00:00:002007Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.9257840Koningsberger JC, Chott A, Logtenberg T, Wiegman LJ, Blumberg RS, van Berge Henegouwen GP, Balk SPJournal of immunology (Baltimore, Md. : 1950)TCR expression in human fetal intestine and identification of an early T cell receptor beta-chain transcript. J Immunol. 1997 Aug 15; 159(4):1775-82.J Immunol1997-08-15T00:00:001997TCR expression in human fetal intestine and identification of an early T cell receptor beta-chain transcript.9444960Sun Z, Pan J, Bubley G, Balk SPOncogeneFrequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene. 1997 Dec 18; 15(25):3121-5.Oncogene1997-12-18T00:00:001997Frequent abnormalities of TSG101 transcripts in human prostate cancer.12525533Balk SP, Ko YJ, Bubley GJJournal of clinical oncology : official journal of the American Society of Clinical OncologyBiology of prostate-specific antigen. J Clin Oncol. 2003 Jan 15; 21(2):383-91.J Clin Oncol2003-01-15T00:00:002003Biology of prostate-specific antigen.10809957Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, Tahir SM, Patton KT, Blumberg RS, Porcelli S, Chott A, Balk SPImmunologyCD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 2000 May; 100(1):37-47.Immunology2000-05-01T00:00:002000CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes.11106683Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda MJournal of the National Cancer InstituteHer-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 06; 92(23):1918-25.J Natl Cancer Inst2000-12-06T00:00:002000Her-2-neu expression and progression toward androgen independence in human prostate cancer.11207260Dao T, Exley M, Mehal WZ, Tahir SM, Snapper S, Taniguchi M, Balk SP, Crispe INJournal of immunology (Baltimore, Md. : 1950)Involvement of CD1 in peripheral deletion of T lymphocytes is independent of NK T cells. J Immunol. 2001 Mar 01; 166(5):3090-7.J Immunol2001-03-01T00:00:002001Involvement of CD1 in peripheral deletion of T lymphocytes is independent of NK T cells.11564825Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MAJournal of immunology (Baltimore, Md. : 1950)Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol. 2001 Oct 01; 167(7):4046-50.J Immunol2001-10-01T00:00:002001Loss of IFN-gamma production by invariant NK T cells in advanced cancer.Authorship 9790632Authorship 9789281Authorship 97904526795359Balk SP, Mescher MFJournal of supramolecular structure and cellular biochemistrySpecific reversal of cytolytic T lymphocyte--target cell interaction. J Supramol Struct Cell Biochem. 1981; 16(1):43-52.J Supramol Struct Cell Biochem1981-01-01T00:00:001981Specific reversal of cytolytic T lymphocyte--target cell interaction.6980567Mescher MF, Balk SP, Burakoff SJ, Herrmann SHAdvances in experimental medicine and biologyCytolytic T lymphocyte recognition of subcellular antigen. Adv Exp Med Biol. 1982; 146:41-55.Adv Exp Med Biol1982-01-01T00:00:001982Cytolytic T lymphocyte recognition of subcellular antigen.28414609Bubley GJ, Balk SPJournal of clinical oncology : official journal of the American Society of Clinical OncologyAssociation Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. J Clin Oncol. 2017 07 01; 35(19):2103-2105.J Clin Oncol2017-04-17T00:00:002017Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.9241247Sun Z, Pan J, Balk SPNucleic acids researchAndrogen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes. Nucleic Acids Res. 1997 Aug 15; 25(16):3318-25.Nucleic Acids Res1997-08-15T00:00:001997Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes.12960113Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJClinical cancer research : an official journal of the American Association for Cancer ResearchMinimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. Clin Cancer Res. 2003 Aug 15; 9(9):3282-7.Clin Cancer Res2003-08-15T00:00:002003Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.9207002Exley M, Garcia J, Balk SP, Porcelli SThe Journal of experimental medicineRequirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med. 1997 Jul 07; 186(1):109-20.J Exp Med1997-07-07T00:00:001997Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells.9250156Chott A, Gerdes D, Spooner A, Mosberger I, Kummer JA, Ebert EC, Blumberg RS, Balk SPThe American journal of pathologyIntraepithelial lymphocytes in normal human intestine do not express proteins associated with cytolytic function. Am J Pathol. 1997 Aug; 151(2):435-42.Am J Pathol1997-08-01T00:00:001997Intraepithelial lymphocytes in normal human intestine do not express proteins associated with cytolytic function.10889161Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, Hagen SJ, Kanauchi O, Motoki K, Sakai T, Terhorst C, Koezuka Y, Podolsky DK, Blumberg RSGastroenterologyActivation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 2000 Jul; 119(1):119-28.Gastroenterology2000-07-01T00:00:002000Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice.10553057Zeng D, Gazit G, Dejbakhsh-Jones S, Balk SP, Snapper S, Taniguchi M, Strober SJournal of immunology (Baltimore, Md. : 1950)Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus. J Immunol. 1999 Nov 15; 163(10):5338-45.J Immunol1999-11-15T00:00:001999Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus.12613202Cheng S, Balk SPCancer treatment and researchSteroid hormone receptor signaling in cancer. Cancer Treat Res. 2003; 115:293-318.Cancer Treat Res2003-01-01T00:00:002003Steroid hormone receptor signaling in cancer.10544194Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein JThe Journal of experimental medicineCD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med. 1999 Nov 01; 190(9):1215-26.J Exp Med1999-11-01T00:00:001999CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site.20304831Porcelli S, Brenner MB, Greenstein JL, Terhorst C, Balk SP, Bleicher PAJournal of immunology (Baltimore, Md. : 1950)Recognition of Cluster of Differentiation 1 Antigens by Human CD4-CD8- CytolyticT Lymphocyte. Nature. 1989. 341: 447-450. 1989. J Immunol. 2010 Apr 01; 184(7):3306-9.J Immunol2010-04-01T00:00:002010Recognition of Cluster of Differentiation 1 Antigens by Human CD4-CD8- CytolyticT Lymphocyte. Nature. 1989. 341: 447-450. 1989.12231070Balk SPUrologyAndrogen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9.Urology2002-09-01T00:00:002002Androgen receptor as a target in androgen-independent prostate cancer.15311058Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SPThe Journal of urologyAndrogen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol. 2004 Sep; 172(3):1140-4.J Urol2004-09-01T00:00:002004Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers.15538748Fu XS, Choi E, Bubley GJ, Balk SPThe ProstateIdentification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate. 2005 May 15; 63(3):215-21.Prostate2005-05-15T00:00:002005Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.15598662Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg ANThe Journal of biological chemistryThe androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem. 2005 Feb 25; 280(8):6511-9.J Biol Chem2004-12-14T00:00:002004The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.15623502Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, Lanz RB, Zoumpourlis VC, Schwartz RJThe Journal of biological chemistryRecruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J Biol Chem. 2005 Mar 04; 280(9):7786-92.J Biol Chem2004-12-28T00:00:002004Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene.16091469Yue SC, Shaulov A, Wang R, Balk SP, Exley MAProceedings of the National Academy of Sciences of the United States of AmericaCD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12. Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11811-6.Proc Natl Acad Sci U S A2005-08-09T00:00:002005CD1d ligation on human monocytes directly signals rapid NF-kappaB activation and production of bioactive IL-12.17667522van der Vliet HJ, Koon HB, Atkins MB, Balk SP, Exley MAJournal of immunotherapy (Hagerstown, Md. : 1997)Exploiting regulatory T-cell populations for the immunotherapy of cancer. J Immunother. 2007 Sep; 30(6):591-5.J Immunother2007-09-01T00:00:002007Exploiting regulatory T-cell populations for the immunotherapy of cancer.14632651Exley MA, Bigley NJ, Cheng O, Shaulov A, Tahir SM, Carter QL, Garcia J, Wang C, Patten K, Stills HF, Alt FW, Snapper SB, Balk SPImmunologyInnate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology. 2003 Dec; 110(4):519-26.Immunology2003-12-01T00:00:002003Innate immune response to encephalomyocarditis virus infection mediated by CD1d.11309325Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A, Hannah A, Balk SP, Bubley GJClinical cancer research : an official journal of the American Association for Cancer ResearchA multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001 Apr; 7(4):800-5.Clin Cancer Res2001-04-01T00:00:002001A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.1717564Blumberg RS, Terhorst C, Bleicher P, McDermott FV, Allan CH, Landau SB, Trier JS, Balk SPJournal of immunology (Baltimore, Md. : 1950)Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol. 1991 Oct 15; 147(8):2518-24.J Immunol1991-10-15T00:00:001991Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells.12847287Gillessen S, Naumov YN, Nieuwenhuis EE, Exley MA, Lee FS, Mach N, Luster AD, Blumberg RS, Taniguchi M, Balk SP, Strominger JL, Dranoff G, Wilson SBProceedings of the National Academy of Sciences of the United States of AmericaCD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion. Proc Natl Acad Sci U S A. 2003 Jul 22; 100(15):8874-9.Proc Natl Acad Sci U S A2003-07-07T00:00:002003CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion.Authorship 993169928663228Zang T, Taplin ME, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA, Blair IA, Penning TMEndocrine-related cancerTesticular vs adrenal sources of hydroxy-androgens in prostate cancer. Endocr Relat Cancer. 2017 08; 24(8):393-404.Endocr Relat Cancer2017-06-29T00:00:002017Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.15544494Ko YJ, Balk SPCurrent pharmaceutical biotechnologyTargeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol. 2004 Oct; 5(5):459-70.Curr Pharm Biotechnol2004-10-01T00:00:002004Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers.18301781Balk SP, Knudsen KENuclear receptor signalingAR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008 Feb 01; 6:e001.Nucl Recept Signal2008-02-01T00:00:002008AR, the cell cycle, and prostate cancer.19351832Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff PCancer researchThe role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009 Apr 15; 69(8):3356-63.Cancer Res2009-04-07T00:00:002009The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.7505446Brooks EG, Balk SP, Aupeix K, Colonna M, Strominger JL, Groh-Spies VProceedings of the National Academy of Sciences of the United States of AmericaHuman T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells. Proc Natl Acad Sci U S A. 1993 Dec 15; 90(24):11787-91.Proc Natl Acad Sci U S A1993-12-15T00:00:001993Human T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells.8506952Davis TH, Yockey CE, Balk SPThe American journal of pathologyDetection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis. Am J Pathol. 1993 Jun; 142(6):1841-7.Am J Pathol1993-06-01T00:00:001993Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis.17404092van der Vliet HJ, van der Vliet HJ, Koon HB, Yue SC, Uzunparmak B, Seery V, Gavin MA, Rudensky AY, Atkins MB, Balk SP, Exley MAClinical cancer research : an official journal of the American Association for Cancer ResearchEffects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007 Apr 01; 13(7):2100-8.Clin Cancer Res2007-04-01T00:00:002007Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.19647299Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MGUrologyDetection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA. Urology. 2009 Nov; 74(5):1156-61.Urology2009-08-03T00:00:002009Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.2577325Balk S, Terhorst CImmunology seriesRelationship between the T-cell receptor-T3 complex and Thy-1. Immunol Ser. 1989; 45:411-6.Immunol Ser1989-01-01T00:00:001989Relationship between the T-cell receptor-T3 complex and Thy-1.21712345Cai C, Balk SPEndocrine-related cancerIntratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011 Oct; 18(5):R175-82.Endocr Relat Cancer2011-08-30T00:00:002011Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.22981538Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V, Balk SP, O'Shea D, O'Farrelly C, Exley MAImmunityAdipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity. 2012 Sep 21; 37(3):574-87.Immunity2012-09-13T00:00:002012Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production.16510604Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SPCancer researchIncreased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006 Mar 01; 66(5):2815-25.Cancer Res2006-03-01T00:00:002006Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.9293397Christ AD, Colgan SP, Balk SP, Blumberg RSImmunology lettersHuman intestinal epithelial cell lines produce factor(s) that inhibit CD3-mediated T-lymphocyte proliferation. Immunol Lett. 1997 Aug; 58(3):159-65.Immunol Lett1997-08-01T00:00:001997Human intestinal epithelial cell lines produce factor(s) that inhibit CD3-mediated T-lymphocyte proliferation.Authorship 10111281128893901Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye HClinical cancer research : an official journal of the American Association for Cancer ResearchExpression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clin Cancer Res. 2017 Nov 15; 23(22):6812-6822.Clin Cancer Res2017-09-11T00:00:002017Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.11535819Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SPProceedings of the National Academy of Sciences of the United States of AmericaProstatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A. 2001 Sep 11; 98(19):10823-8.Proc Natl Acad Sci U S A2001-09-04T00:00:002001Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.1702817Balk SP, Bleicher PA, Terhorst CJournal of immunology (Baltimore, Md. : 1950)Isolation and expression of cDNA encoding the murine homologues of CD1. J Immunol. 1991 Jan 15; 146(2):768-74.J Immunol1991-01-15T00:00:001991Isolation and expression of cDNA encoding the murine homologues of CD1.17239271Reddy GK, Balk SPClinical genitourinary cancerClinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer. Clin Genitourin Cancer. 2006 Dec; 5(3):187-9.Clin Genitourin Cancer2006-12-01T00:00:002006Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer.19477425Shen HC, Balk SPCancer cellDevelopment of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell. 2009 Jun 02; 15(6):461-3.Cancer Cell2009-06-02T00:00:002009Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.11328859Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Jänne OA, Palvimo JJ, Pestell RGMolecular endocrinology (Baltimore, Md.)Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol. 2001 May; 15(5):797-811.Mol Endocrinol2001-05-01T00:00:002001Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner.16428447Chen SY, Wulf G, Zhou XZ, Rubin MA, Lu KP, Balk SPMolecular and cellular biologyActivation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol. 2006 Feb; 26(3):929-39.Mol Cell Biol2006-02-01T00:00:002006Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.17804755Hodgson MC, Astapova I, Hollenberg AN, Balk SPCancer researchActivity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res. 2007 Sep 01; 67(17):8388-95.Cancer Res2007-09-01T00:00:002007Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.2463622Balk SP, Bleicher PA, Terhorst CProceedings of the National Academy of Sciences of the United States of AmericaIsolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci U S A. 1989 Jan; 86(1):252-6.Proc Natl Acad Sci U S A1989-01-01T00:00:001989Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule.19622840Chen S, Kesler CT, Paschal BM, Balk SPThe Journal of biological chemistryAndrogen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1. J Biol Chem. 2009 Sep 18; 284(38):25576-84.J Biol Chem2009-07-21T00:00:002009Androgen receptor phosphorylation and activity are regulated by an association with protein phosphatase 1.18261838Shaulov A, Yue S, Wang R, Joyce RM, Balk SP, Kim HT, Avigan DE, Uhl L, Sackstein R, Exley MAExperimental hematologyPeripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival. Exp Hematol. 2008 Apr; 36(4):464-72.Exp Hematol2008-02-08T00:00:002008Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival.18642328Kaur R, Yuan X, Lu ML, Balk SPThe ProstateIncreased PAK6 expression in prostate cancer and identification of PAK6 associated proteins. Prostate. 2008 Oct 01; 68(14):1510-6.Prostate2008-10-01T00:00:002008Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.18667312Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, Didonato M, Nagle A, Warmuth M, Balk SP, Peters EC, Gray NSBioorganic & medicinal chemistry lettersClinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 2008 Nov 15; 18(22):5916-9.Bioorg Med Chem Lett2008-07-18T00:00:002008Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.Authorship 1023544329091262Exley MA, Wilson SB, Balk SPCurrent protocols in immunologyIsolation and Functional Use of Human NKT Cells. Curr Protoc Immunol. 2017 Nov 01; 119:14.11.1-14.11.20.Curr Protoc Immunol2017-11-01T00:00:002017Isolation and Functional Use of Human NKT Cells.1515136Bubley GJ, Ashburner BP, Balk SP, Ara G, Varshaney A, Teicher BABioTechniquesIdentification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei. Biotechniques. 1992 May; 12(5):694, 696, 698.Biotechniques1992-05-01T00:00:001992Identification of cis-diamminedichloroplatinum(II) adducts in DNA from drug-treated human cell nuclei.11332651Probert CS, Chott A, Saubermann LJ, Stevens AC, Balk SP, Blumberg RSJournal of clinical immunologyPrevalence of an ulcerative colitis-associated CD8+ T cell receptor beta-chain CDR3-region motif and its association with disease activity. J Clin Immunol. 2001 Mar; 21(2):126-34.J Clin Immunol2001-03-01T00:00:002001Prevalence of an ulcerative colitis-associated CD8+ T cell receptor beta-chain CDR3-region motif and its association with disease activity.17823122Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SPThe Journal of biological chemistryActivation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem. 2007 Nov 09; 282(45):32689-98.J Biol Chem2007-09-06T00:00:002007Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.11823474Exley MA, He Q, Cheng O, Wang RJ, Cheney CP, Balk SP, Koziel MJJournal of immunology (Baltimore, Md. : 1950)Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver. J Immunol. 2002 Feb 15; 168(4):1519-23.J Immunol2002-02-15T00:00:002002Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver.21606417Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PWJournal of clinical oncology : official journal of the American Society of Clinical OncologySLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.J Clin Oncol2011-05-23T00:00:002011SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.17234760Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan XCancer researchSOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res. 2007 Jan 15; 67(2):528-36.Cancer Res2007-01-15T00:00:002007SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.19111796Yuan X, Balk SPUrologic oncologyMechanisms mediating androgen receptor reactivation after castration. Urol Oncol. 2009 Jan-Feb; 27(1):36-41.Urol Oncol2009-01-01T00:00:002009Mechanisms mediating androgen receptor reactivation after castration.Authorship 1032180329258679Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GVEuropean urologyRole of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 05; 73(5):715-723.Eur Urol2017-12-16T00:00:002017Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.19949077Yue SC, Nowak M, Shaulov-Kask A, Wang R, Yue D, Balk SP, Exley MAJournal of immunology (Baltimore, Md. : 1950)Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol. 2010 Jan 01; 184(1):268-76.J Immunol2009-11-30T00:00:002009Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo.330 Brookline AveBeth Israel Deaconess Med CtrMedicine, HIM 1047330 Brookline AveBoston02215MA21646050Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, Balk SPClinical immunology (Orlando, Fla.)Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol. 2011 Aug; 140(2):184-95.Clin Immunol2011-05-13T00:00:002011Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.19632176Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown MCellAndrogen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23; 138(2):245-56.Cell2009-07-23T00:00:002009Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.19815488Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WKClinical genitourinary cancerActivity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2.Clin Genitourin Cancer2009-10-01T00:00:002009Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.20593019Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MAPloS oneDefective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with a-galactosylceramide. PLoS One. 2010 Jun 25; 5(6):e11311.PLoS One2010-06-25T00:00:002010Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with a-galactosylceramide.23306204Wang H, He L, Ma F, Regan MM, Balk SP, Richardson AL, Yuan XThe Journal of biological chemistrySOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/ß-catenin activation in breast cancer. J Biol Chem. 2013 Mar 01; 288(9):6478-87.J Biol Chem2013-01-10T00:00:002013SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/ß-catenin activation in breast cancer.18394010Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, Sukhatme VP, Iliopoulos O, Balk S, Bubley GJBJU internationalHypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008 Aug; 102(3):358-63.BJU Int2008-04-03T00:00:002008Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.7517575Balk SP, Burke S, Polischuk JE, Frantz ME, Yang L, Porcelli S, Colgan SP, Blumberg RSScience (New York, N.Y.)Beta 2-microglobulin-independent MHC class Ib molecule expressed by human intestinal epithelium. Science. 1994 Jul 08; 265(5169):259-62.Science1994-07-08T00:00:001994Beta 2-microglobulin-independent MHC class Ib molecule expressed by human intestinal epithelium.18980990Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NCClinical cancer research : an official journal of the American Association for Cancer ResearchGeneration of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.Clin Cancer Res2008-11-01T00:00:002008Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.12394769Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros CThe Journal of urologySerum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy. J Urol. 2002 Nov; 168(5):2249-52.J Urol2002-11-01T00:00:002002Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.9428763Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA, Atkinson MA, Balk SP, Strominger JL, Hafler DANatureExtreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998 Jan 08; 391(6663):177-81.Nature1998-01-08T00:00:001998Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes.9761945Probert CS, Aitken EW, Saubermann LJ, Balk SP, Blumberg RSChemical immunologyT-cell receptor usage in the intestine. Chem Immunol. 1998; 71:27-39.Chem Immunol1998-01-01T00:00:001998T-cell receptor usage in the intestine.9488653Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, Balk SP, Cotter RJ, Brutkiewicz RRScience (New York, N.Y.)Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science. 1998 Mar 06; 279(5356):1541-4.Science1998-03-06T00:00:001998Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol.6787131Balk SP, Mescher MFJournal of immunology (Baltimore, Md. : 1950)Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells. J Immunol. 1981 Jul; 127(1):51-7.J Immunol1981-07-01T00:00:001981Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.6976213Balk SP, Mescher MFCellular immunologyCytolytic T lymphocyte mediated chromium-51 release versus spontaneous release from blast and spleen cell targets at low temperatures. Cell Immunol. 1981 Nov 15; 65(1):201-5.Cell Immunol1981-11-15T00:00:001981Cytolytic T lymphocyte mediated chromium-51 release versus spontaneous release from blast and spleen cell targets at low temperatures.9036959Teitell M, Holcombe HR, Brossay L, Hagenbaugh A, Jackson MJ, Pond L, Balk SP, Terhorst C, Peterson PA, Kronenberg MJournal of immunology (Baltimore, Md. : 1950)Nonclassical behavior of the mouse CD1 class I-like molecule. J Immunol. 1997 Mar 01; 158(5):2143-9.J Immunol1997-03-01T00:00:001997Nonclassical behavior of the mouse CD1 class I-like molecule.